+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Bioidentical Hormones Market - Global Forecast 2026-2032- Product Image
Bioidentical Hormones Market - Global Forecast 2026-2032- Product Image
Sale

Bioidentical Hormones Market - Global Forecast 2026-2032

  • Report

  • 194 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 6011384
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Bioidentical Hormones Market is projected to reach USD 1.55 Billion in 2026. It is expected to continue growing at a CAGR of 8.01%, reaching USD 2.47 Billion by 2032.

Bioidentical hormones are hormone therapies with the same chemical structure as endogenous human hormones, most often including estradiol, progesterone, and testosterone. Demand is shaped by menopause symptom management, endocrine care, aging populations, and rising patient interest in individualized treatment pathways.

The market is defined by a critical distinction: regulated, agency-approved hormone products that may contain bioidentical molecules versus compounded bioidentical hormone formulations that are not approved by regulators for safety, effectiveness, or manufacturing consistency. This distinction is central to clinical adoption, payer confidence, prescriber trust, and long-term market credibility.

Transformative Shifts in the Bioidentical Hormones Landscape

The bioidentical hormones landscape is shifting from broad lifestyle positioning toward evidence-based, risk-stratified care. Clinical guidance from organizations such as The Menopause Society emphasizes that hormone therapy is the most effective treatment for vasomotor symptoms and can be appropriate for many symptomatic women younger than 60 years or within 10 years of menopause onset.

At the same time, regulators and medical societies continue to scrutinize compounded hormone products because of variable dosing, limited clinical evidence, and quality-control concerns. Growth is increasingly tied to transparent labeling, physician-supervised treatment, validated diagnostic assessment, pharmacovigilance, and preference for approved formulations when available.

Cumulative Impact of Artificial Intelligence on Hormone Therapy

Artificial intelligence is beginning to influence the bioidentical hormones ecosystem through clinical decision support, adverse-event signal detection, patient segmentation, and adherence monitoring. AI-enabled analytics can help clinicians evaluate symptom patterns, comorbidities, medication histories, laboratory results, and contraindication risks using structured health data.

The cumulative impact will depend on governance. AI should support, not replace, licensed clinical judgment, particularly because hormone therapy requires individualized assessment of cardiovascular, thrombotic, breast cancer, liver, and metabolic risk factors. Secure data handling, algorithm transparency, clinical validation, and bias testing are becoming essential requirements for scalable AI deployment.

Key Regional Insights for Bioidentical Hormones

North America remains highly influential due to established menopause care networks, specialized clinics, FDA and Health Canada oversight, and active debate over compounded bioidentical hormones. Europe is shaped by EMA-aligned regulation, national health technology assessment, and strong clinical guidance from bodies such as NICE, supporting evidence-led prescribing and careful benefit-risk assessment.

Asia-Pacific is gaining momentum as Japan, Australia, South Korea, China, and India face population aging, rising life expectancy, and growing women’s health awareness. Latin America shows expanding private-sector demand, led by Brazil and Mexico, while access, reimbursement, and regulatory consistency vary widely across countries. The Middle East and Africa are earlier-stage markets, with urban private care, medical tourism, specialist endocrinology services, and improving pharmaceutical regulation driving selective growth.

Key Group Insights Across Major Economic and Policy Blocs

The European Union and G7 markets generally set the benchmark for pharmacovigilance, prescribing standards, product quality, and evidence-based menopause management, which supports adoption of approved hormone therapies and limits unsupported claims. NATO member markets overlap with many high-income healthcare systems where clinical governance, defense health systems, and regulated supply chains strengthen expectations for safe, traceable hormone products.

BRICS countries create long-term volume potential through large populations, expanding middle-class healthcare access, and rising chronic disease and endocrine care needs, although regulatory maturity and access pathways differ by country. ASEAN markets are advancing through women’s health awareness, private clinics, and digital health adoption, while GCC countries benefit from healthcare investment, specialist care expansion, and demand for premium, physician-led endocrine and wellness services.

Key Country Insights for Bioidentical Hormones

In the United States and Canada, market development is strongly influenced by regulatory clarity, menopause care guidelines, prescriber education, and the distinction between approved hormone products and compounded formulations. Mexico and Brazil are expanding through private healthcare access and growing demand for women’s health services, though product oversight, affordability, and reimbursement remain uneven.

The United Kingdom, Germany, France, Italy, and Spain are guided by national prescribing frameworks and broader European safety standards, while Russia presents a more fragmented regulatory and access environment. China and India offer scale as awareness rises and healthcare access expands, Japan and South Korea emphasize regulated pharmaceutical quality and aging-population care, and Australia combines strong clinical guidance with an active menopause-care market supported by high health literacy.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated products, transparent risk communication, and strict separation between approved bioidentical-molecule therapies and compounded preparations. Claims should align with regulator-approved labeling and recognized clinical guidelines to reduce compliance risk and strengthen physician, payer, and patient trust.

Organizations should invest in pharmacovigilance, real-world evidence, prescriber education, quality assurance, and supply-chain traceability across manufacturing and compounding networks. AI tools can improve engagement, monitoring, and risk stratification, but they require clinical oversight, data privacy controls, bias assessment, and documented validation before being integrated into hormone treatment workflows.

Research Methodology

This executive summary is based on secondary research triangulation using regulatory guidance, clinical society statements, public health data, and peer-reviewed literature. Sources considered include agencies and institutions such as the FDA, EMA, Health Canada, MHRA, TGA, PMDA, The Menopause Society, ACOG, Endocrine Society, NICE, WHO, OECD, and UN population data.

The analysis emphasizes verified, data-backed insights and excludes unsupported market-size claims, anecdotal promotional statements, and unverified efficacy assertions. Regional and country interpretations were developed by assessing regulatory maturity, demographic trends, healthcare access, clinical adoption, pharmacovigilance requirements, and women’s health policy momentum.

Conclusion

The bioidentical hormones market is positioned for steady evolution as aging demographics, menopause awareness, endocrine care needs, and digital health adoption reshape demand. However, sustainable growth depends on evidence, regulatory compliance, product quality, and clear communication about the difference between approved hormone therapies and compounded products.

Leaders that combine scientific credibility, patient-centered care, robust safety monitoring, responsible AI adoption, and guideline-aligned education will be best placed to compete. The strongest opportunities will emerge where clinical need, regulatory trust, provider education, and accessible treatment pathways converge.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Bioidentical Hormones Market, by Type
7.1. Introduction
7.2. Single-Hormone Products
7.3. Multi-Hormone Products
8. Bioidentical Hormones Market, by Hormone Class
8.1. Introduction
8.2. Estrogens
8.3. Progesterone
8.4. Androgens
9. Bioidentical Hormones Market, by Dosage Form
9.1. Introduction
9.2. Creams
9.3. Gels
9.4. Sprays
9.5. Tablets
9.6. Capsule
10. Bioidentical Hormones Market, by Route of Administration
10.1. Introduction
10.2. Injectable
10.3. Oral
10.4. Topical
10.5. Vaginal
11. Bioidentical Hormones Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Home Care
11.4. Hospitals
12. Bioidentical Hormones Market, by Gender
12.1. Introduction
12.2. Female
12.3. Male
13. Bioidentical Hormones Market, by Region
13.1. Asia-Pacific
13.2. Europe
13.3. North America
13.4. Latin America
13.5. Africa
13.6. Middle East
14. Bioidentical Hormones Market, by Group
14.1. NATO
14.2. G7
14.3. BRICS
14.4. European Union
14.5. ASEAN
14.6. GCC
15. Bioidentical Hormones Market, by Country
15.1. China
15.2. United States
15.3. Japan
15.4. India
15.5. Germany
15.6. United Kingdom
15.7. Australia
15.8. France
15.9. South Korea
15.10. Italy
15.11. Canada
15.12. Russia
15.13. Brazil
15.14. Mexico
15.15. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Abbott Laboratories
17.2. Actiza Pharmaceutical Private Limited
17.3. Amneal Pharmaceuticals
17.4. Bayer AG
17.5. Besins Healthcare
17.6. BioTE Medical LLC
17.7. Changchun GeneScience Pharmaceuticals Co., Ltd.
17.8. Defy Medical
17.9. Ferring Pharmaceuticals
17.10. Full Life Wellness Center
17.11. Gedeon Richter PLC
17.12. Johnson & Johnson Services Inc.
17.13. Mayne Pharma Group Limited
17.14. Merck KGaA
17.15. Mithra Pharmaceuticals S.A.
17.16. Novartis AG
17.17. Noven Pharmaceuticals Inc.
17.18. Organon & Co.
17.19. Orion Corporation
17.20. Padagis US LLC
17.21. Papillon Medical
17.22. Pfizer Inc.
17.23. SottoPelle
17.24. Teva Pharmaceutical Industries Ltd.
17.25. TherapeuticsMD Inc.
List of Figures
FIGURE 1. GLOBAL BIOIDENTICAL HORMONES MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL BIOIDENTICAL HORMONES MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL BIOIDENTICAL HORMONES MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL BIOIDENTICAL HORMONES MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONE CLASS, 2025 VS 2032 (%)
FIGURE 9. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONE CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
FIGURE 11. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY GENDER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY GENDER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL BIOIDENTICAL HORMONES MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL BIOIDENTICAL HORMONES MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL BIOIDENTICAL HORMONES MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL SINGLE-HORMONE PRODUCTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL SINGLE-HORMONE PRODUCTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL SINGLE-HORMONE PRODUCTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL MULTI-HORMONE PRODUCTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL MULTI-HORMONE PRODUCTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL MULTI-HORMONE PRODUCTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONE CLASS, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL ESTROGENS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL ESTROGENS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL ESTROGENS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL PROGESTERONE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL PROGESTERONE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL PROGESTERONE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL ANDROGENS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL ANDROGENS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL ANDROGENS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL CREAMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL CREAMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL CREAMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL GELS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL GELS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL GELS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL SPRAYS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL SPRAYS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL SPRAYS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL TABLETS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL CAPSULE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL CAPSULE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL CAPSULE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL VAGINAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL VAGINAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL VAGINAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL HOME CARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL HOME CARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL HOME CARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL FEMALE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL FEMALE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL FEMALE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL MALE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL MALE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL MALE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. ASIA-PACIFIC BIOIDENTICAL HORMONES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. ASIA-PACIFIC BIOIDENTICAL HORMONES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 69. ASIA-PACIFIC BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONE CLASS, 2017-2032 (USD MILLION)
TABLE 70. ASIA-PACIFIC BIOIDENTICAL HORMONES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 71. ASIA-PACIFIC BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 72. ASIA-PACIFIC BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 73. ASIA-PACIFIC BIOIDENTICAL HORMONES MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 74. EUROPE BIOIDENTICAL HORMONES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. EUROPE BIOIDENTICAL HORMONES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 76. EUROPE BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONE CLASS, 2017-2032 (USD MILLION)
TABLE 77. EUROPE BIOIDENTICAL HORMONES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 78. EUROPE BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 79. EUROPE BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 80. EUROPE BIOIDENTICAL HORMONES MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 81. NORTH AMERICA BIOIDENTICAL HORMONES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. NORTH AMERICA BIOIDENTICAL HORMONES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 83. NORTH AMERICA BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONE CLASS, 2017-2032 (USD MILLION)
TABLE 84. NORTH AMERICA BIOIDENTICAL HORMONES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 85. NORTH AMERICA BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 86. NORTH AMERICA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 87. NORTH AMERICA BIOIDENTICAL HORMONES MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 88. LATIN AMERICA BIOIDENTICAL HORMONES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. LATIN AMERICA BIOIDENTICAL HORMONES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 90. LATIN AMERICA BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONE CLASS, 2017-2032 (USD MILLION)
TABLE 91. LATIN AMERICA BIOIDENTICAL HORMONES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 92. LATIN AMERICA BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 93. LATIN AMERICA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 94. LATIN AMERICA BIOIDENTICAL HORMONES MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 95. AFRICA BIOIDENTICAL HORMONES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. AFRICA BIOIDENTICAL HORMONES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 97. AFRICA BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONE CLASS, 2017-2032 (USD MILLION)
TABLE 98. AFRICA BIOIDENTICAL HORMONES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 99. AFRICA BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 100. AFRICA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 101. AFRICA BIOIDENTICAL HORMONES MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 102. MIDDLE EAST BIOIDENTICAL HORMONES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. MIDDLE EAST BIOIDENTICAL HORMONES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 104. MIDDLE EAST BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONE CLASS, 2017-2032 (USD MILLION)
TABLE 105. MIDDLE EAST BIOIDENTICAL HORMONES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 106. MIDDLE EAST BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 107. MIDDLE EAST BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 108. MIDDLE EAST BIOIDENTICAL HORMONES MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 110. NATO BIOIDENTICAL HORMONES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 111. NATO BIOIDENTICAL HORMONES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 112. NATO BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONE CLASS, 2017-2032 (USD MILLION)
TABLE 113. NATO BIOIDENTICAL HORMONES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 114. NATO BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 115. NATO BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 116. NATO BIOIDENTICAL HORMONES MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 117. G7 BIOIDENTICAL HORMONES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 118. G7 BIOIDENTICAL HORMONES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 119. G7 BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONE CLASS, 2017-2032 (USD MILLION)
TABLE 120. G7 BIOIDENTICAL HORMONES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 121. G7 BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 122. G7 BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 123. G7 BIOIDENTICAL HORMONES MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 124. BRICS BIOIDENTICAL HORMONES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 125. BRICS BIOIDENTICAL HORMONES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 126. BRICS BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONE CLASS, 2017-2032 (USD MILLION)
TABLE 127. BRICS BIOIDENTICAL HORMONES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 128. BRICS BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 129. BRICS BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 130. BRICS BIOIDENTICAL HORMONES MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 131. EUROPEAN UNION BIOIDENTICAL HORMONES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 132. EUROPEAN UNION BIOIDENTICAL HORMONES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 133. EUROPEAN UNION BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONE CLASS, 2017-2032 (USD MILLION)
TABLE 134. EUROPEAN UNION BIOIDENTICAL HORMONES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 135. EUROPEAN UNION BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 136. EUROPEAN UNION BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 137. EUROPEAN UNION BIOIDENTICAL HORMONES MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 138. ASEAN BIOIDENTICAL HORMONES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 139. ASEAN BIOIDENTICAL HORMONES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 140. ASEAN BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONE CLASS, 2017-2032 (USD MILLION)
TABLE 141. ASEAN BIOIDENTICAL HORMONES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 142. ASEAN BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 143. ASEAN BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 144. ASEAN BIOIDENTICAL HORMONES MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 145. GCC BIOIDENTICAL HORMONES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 146. GCC BIOIDENTICAL HORMONES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 147. GCC BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONE CLASS, 2017-2032 (USD MILLION)
TABLE 148. GCC BIOIDENTICAL HORMONES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 149. GCC BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 150. GCC BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 151. GCC BIOIDENTICAL HORMONES MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 152. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 153. CHINA BIOIDENTICAL HORMONES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 154. CHINA BIOIDENTICAL HORMONES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 155. CHINA BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONE CLASS, 2017-2032 (USD MILLION)
TABLE 156. CHINA BIOIDENTICAL HORMONES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 157. CHINA BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 158. CHINA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 159. CHINA BIOIDENTICAL HORMONES MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 160. UNITED STATES BIOIDENTICAL HORMONES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 161. UNITED STATES BIOIDENTICAL HORMONES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 162. UNITED STATES BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONE CLASS, 2017-2032 (USD MILLION)
TABLE 163. UNITED STATES BIOIDENTICAL HORMONES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 164. UNITED STATES BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 165. UNITED STATES BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 166. UNITED STATES BIOIDENTICAL HORMONES MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 167. JAPAN BIOIDENTICAL HORMONES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 168. JAPAN BIOIDENTICAL HORMONES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 169. JAPAN BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONE CLASS, 2017-2032 (USD MILLION)
TABLE 170. JAPAN BIOIDENTICAL HORMONES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 171. JAPAN BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 172. JAPAN BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 173. JAPAN BIOIDENTICAL HORMONES MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 174. INDIA BIOIDENTICAL HORMONES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 175. INDIA BIOIDENTICAL HORMONES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 176. INDIA BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONE CLASS, 2017-2032 (USD MILLION)
TABLE 177. INDIA BIOIDENTICAL HORMONES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 178. INDIA BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 179. INDIA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 180. INDIA BIOIDENTICAL HORMONES MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 181. GERMANY BIOIDENTICAL HORMONES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 182. GERMANY BIOIDENTICAL HORMONES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 183. GERMANY BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONE CLASS, 2017-2032 (USD MILLION)
TABLE 184. GERMANY BIOIDENTICAL HORMONES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 185. GERMANY BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 186. GERMANY BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 187. GERMANY BIOIDENTICAL HORMONES MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 188. UNITED KINGDOM BIOIDENTICAL HORMONES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 189. UNITED KINGDOM BIOIDENTICAL HORMONES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 190. UNITED KINGDOM BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONE CLASS, 2017-2032 (USD MILLION)
TABLE 191. UNITED KINGDOM BIOIDENTICAL HORMONES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 192. UNITED KINGDOM BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 193. UNITED KINGDOM BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 194. UNITED KINGDOM BIOIDENTICAL HORMONES MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 195. AUSTRALIA BIOIDENTICAL HORMONES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 196. AUSTRALIA BIOIDENTICAL HORMONES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 197. AUSTRALIA BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONE CLASS, 2017-2032 (USD MILLION)
TABLE 198. AUSTRALIA BIOIDENTICAL HORMONES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 199. AUSTRALIA BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 200. AUSTRALIA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 201. AUSTRALIA BIOIDENTICAL HORMONES MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 202. FRANCE BIOIDENTICAL HORMONES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 203. FRANCE BIOIDENTICAL HORMONES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 204. FRANCE BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONE CLASS, 2017-2032 (USD MILLION)
TABLE 205. FRANCE BIOIDENTICAL HORMONES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 206. FRANCE BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 207. FRANCE BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 208. FRANCE BIOIDENTICAL HORMONES MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 209. SOUTH KOREA BIOIDENTICAL HORMONES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 210. SOUTH KOREA BIOIDENTICAL HORMONES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 211. SOUTH KOREA BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONE CLASS, 2017-2032 (USD MILLION)
TABLE 212. SOUTH KOREA BIOIDENTICAL HORMONES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 213. SOUTH KOREA BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 214. SOUTH KOREA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 215. SOUTH KOREA BIOIDENTICAL HORMONES MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 216. ITALY BIOIDENTICAL HORMONES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 217. ITALY BIOIDENTICAL HORMONES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 218. ITALY BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONE CLASS, 2017-2032 (USD MILLION)
TABLE 219. ITALY BIOIDENTICAL HORMONES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 220. ITALY BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 221. ITALY BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 222. ITALY BIOIDENTICAL HORMONES MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 223. CANADA BIOIDENTICAL HORMONES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 224. CANADA BIOIDENTICAL HORMONES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 225. CANADA BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONE CLASS, 2017-2032 (USD MILLION)
TABLE 226. CANADA BIOIDENTICAL HORMONES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 227. CANADA BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 228. CANADA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 229. CANADA BIOIDENTICAL HORMONES MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 230. RUSSIA BIOIDENTICAL HORMONES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 231. RUSSIA BIOIDENTICAL HORMONES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 232. RUSSIA BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONE CLASS, 2017-2032 (USD MILLION)
TABLE 233. RUSSIA BIOIDENTICAL HORMONES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 234. RUSSIA BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 235. RUSSIA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 236. RUSSIA BIOIDENTICAL HORMONES MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 237. BRAZIL BIOIDENTICAL HORMONES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 238. BRAZIL BIOIDENTICAL HORMONES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 239. BRAZIL BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONE CLASS, 2017-2032 (USD MILLION)
TABLE 240. BRAZIL BIOIDENTICAL HORMONES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 241. BRAZIL BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 242. BRAZIL BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 243. BRAZIL BIOIDENTICAL HORMONES MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 244. MEXICO BIOIDENTICAL HORMONES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 245. MEXICO BIOIDENTICAL HORMONES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 246. MEXICO BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONE CLASS, 2017-2032 (USD MILLION)
TABLE 247. MEXICO BIOIDENTICAL HORMONES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 248. MEXICO BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 249. MEXICO BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 250. MEXICO BIOIDENTICAL HORMONES MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 251. SPAIN BIOIDENTICAL HORMONES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 252. SPAIN BIOIDENTICAL HORMONES MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 253. SPAIN BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONE CLASS, 2017-2032 (USD MILLION)
TABLE 254. SPAIN BIOIDENTICAL HORMONES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 255. SPAIN BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 256. SPAIN BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 257. SPAIN BIOIDENTICAL HORMONES MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 258. GLOBAL BIOIDENTICAL HORMONES MARKET SHARE, BY KEY PLAYER, 2025
TABLE 259. GLOBAL BIOIDENTICAL HORMONES MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • Abbott Laboratories
  • Actiza Pharmaceutical Private Limited
  • Amneal Pharmaceuticals
  • Bayer AG
  • Besins Healthcare
  • BioTE Medical LLC
  • Changchun GeneScience Pharmaceuticals Co., Ltd.
  • Defy Medical
  • Ferring Pharmaceuticals
  • Full Life Wellness Center
  • Gedeon Richter PLC
  • Johnson & Johnson Services Inc.
  • Mayne Pharma Group Limited
  • Merck KGaA
  • Mithra Pharmaceuticals S.A.
  • Novartis AG
  • Noven Pharmaceuticals Inc.
  • Organon & Co.
  • Orion Corporation
  • Padagis US LLC
  • Papillon Medical
  • Pfizer Inc.
  • SottoPelle
  • Teva Pharmaceutical Industries Ltd.
  • TherapeuticsMD Inc.

Table Information

Report AttributeDetails
No. of Pages194
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 1.55 Billion
Forecasted Market Value ( USD ) by 2032 $ 2.47 Billion
Compound Annual Growth Rate8.0%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Bioidentical Hormones Market Report 2026 - Product Image

Bioidentical Hormones Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Bioidentical Hormones - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Bioidentical Hormones - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 140 Pages
  • Global
From
Synthetic Hormone Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Synthetic Hormone Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Hormone Therapy Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Hormone Therapy Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Hormone Therapy Market Report 2026 - Product Image

Hormone Therapy Market Report 2026

  • Report
  • 250 Pages
  • Global
From

About the Bioidentical Hormones Market

Bioidentical hormones are biotechnological products that are chemically identical to hormones naturally produced by the human body. They are used to treat a variety of medical conditions, including menopause, andropause, and hormone imbalances. Bioidentical hormones are typically derived from plant sources, such as yams and soybeans, and are then synthesized in a laboratory to create a product that is identical to the hormones produced by the body. Bioidentical hormones are becoming increasingly popular due to their ability to provide relief from symptoms associated with hormone imbalances without the side effects associated with traditional hormone replacement therapies. They are also seen as a more natural alternative to synthetic hormones. The bioidentical hormones market is growing rapidly, driven by increasing awareness of the benefits of bioidentical hormones and the availability of more affordable products. The market is expected to continue to grow in the coming years as more people become aware of the potential benefits of bioidentical hormones. Some companies in the bioidentical hormones market include BioTE Medical, BHRT Solutions, and Compounding Solutions. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.